Streamline Health Solutions (STRM) Q4 2025 earnings summary

Executive summary

• Fiscal 2024 revenue was $17.9 million, down from $22.6 million in the prior year, mainly due to SaaS non-renewals and lower legacy contract revenue, partially offset by new SaaS bookings.

• Net loss for fiscal 2024 improved to $10.2 million from $18.7 million in fiscal 2023, as the prior year included $10.8 million in non-cash impairment charges.

• SaaS revenue comprised 66% of total revenue in fiscal 2024, up from 62% in fiscal 2023, despite a decline in absolute SaaS revenue to $11.8 million from $14.1 million.

• Book size ACV reached $14 million at fiscal year-end and $14.6 million by April 30, 2025, with $13.1 million implemented.

• New denial prevention functionality was launched within the eValuator platform, expected to significantly increase financial impact for clients.

Financial highlights

• Q4 2024 revenue was $4.7 million, down from $5.4 million in Q4 2023; full-year revenue was $17.9 million, down from $22.6 million in the prior year.

• Net loss for Q4 2024 was $2.1 million, compared to $1.4 million in Q4 2023; full-year net loss improved to $10.2 million from $18.7 million in fiscal 2023.

• Cash and cash equivalents stood at $2.2 million as of January 31, 2025, versus $3.2 million a year earlier.

• Adjusted EBITDA loss for fiscal 2024 was $1.3 million, a slight improvement from $1.4 million in fiscal 2023.

• Booked SaaS ACV as of January 31, 2025, was $14 million, down from $15 million a year earlier, with $3.5 million in new bookings during fiscal 2025.

Outlook and guidance

• Management expects to achieve an adjusted EBITDA positive run rate in the first half of fiscal 2025.

• Enhanced product features and improved client referenceability are anticipated to drive increased bookings in fiscal 2025.

• No specific guidance on bookings timing due to unpredictability of contract closings.